vs
INNOSPEC INC.（IOSP）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是INNOSPEC INC.的1.4倍（$622.0M vs $455.6M），Royalty Pharma plc净利率更高（34.4% vs 10.4%，领先24.0%），Royalty Pharma plc同比增速更快（4.8% vs -2.4%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -4.6%）
Innospec Inc.是一家美国特种化学品企业，前身为奥克泰尔公司及联合奥克泰尔有限公司，旗下设有三大业务板块：高性能化学品业务覆盖个人护理、家居护理、农化、采矿及工业市场；燃料特种化学品业务专注于生产和供应燃油添加剂；油田服务业务则提供钻井、完井及采油相关化学品。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
IOSP vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.4倍
$455.6M
营收增速更快
RPRX
高出7.2%
-2.4%
净利率更高
RPRX
高出24.0%
10.4%
两年增速更快
RPRX
近两年复合增速
-4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $455.6M | $622.0M |
| 净利润 | $47.4M | $214.2M |
| 毛利率 | 28.0% | — |
| 营业利润率 | 10.3% | 62.4% |
| 净利率 | 10.4% | 34.4% |
| 营收同比 | -2.4% | 4.8% |
| 净利润同比 | 167.3% | 2.9% |
| 每股收益（稀释后） | $1.90 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IOSPRPRX
| Q4 25 | $455.6M | $622.0M | ||
| Q3 25 | $441.9M | $609.3M | ||
| Q2 25 | $439.7M | $578.7M | ||
| Q1 25 | $440.8M | $568.2M | ||
| Q4 24 | $466.8M | $593.6M | ||
| Q3 24 | $443.4M | $564.7M | ||
| Q2 24 | $435.0M | $537.3M | ||
| Q1 24 | $500.2M | $568.0M |
净利润IOSPRPRX
| Q4 25 | $47.4M | $214.2M | ||
| Q3 25 | $12.9M | $288.2M | ||
| Q2 25 | $23.5M | $30.2M | ||
| Q1 25 | $32.8M | $238.3M | ||
| Q4 24 | $-70.4M | $208.2M | ||
| Q3 24 | $33.4M | $544.0M | ||
| Q2 24 | $31.2M | $102.0M | ||
| Q1 24 | $41.4M | $4.8M |
毛利率IOSPRPRX
| Q4 25 | 28.0% | — | ||
| Q3 25 | 26.4% | — | ||
| Q2 25 | 28.0% | — | ||
| Q1 25 | 28.4% | — | ||
| Q4 24 | 29.2% | — | ||
| Q3 24 | 28.0% | — | ||
| Q2 24 | 29.2% | — | ||
| Q1 24 | 31.1% | — |
营业利润率IOSPRPRX
| Q4 25 | 10.3% | 62.4% | ||
| Q3 25 | 1.3% | 70.1% | ||
| Q2 25 | 7.8% | 36.3% | ||
| Q1 25 | 9.6% | 94.0% | ||
| Q4 24 | 8.8% | 60.9% | ||
| Q3 24 | 10.3% | — | ||
| Q2 24 | 9.4% | 50.2% | ||
| Q1 24 | 10.1% | -13.0% |
净利率IOSPRPRX
| Q4 25 | 10.4% | 34.4% | ||
| Q3 25 | 2.9% | 47.3% | ||
| Q2 25 | 5.3% | 5.2% | ||
| Q1 25 | 7.4% | 41.9% | ||
| Q4 24 | -15.1% | 35.1% | ||
| Q3 24 | 7.5% | 96.3% | ||
| Q2 24 | 7.2% | 19.0% | ||
| Q1 24 | 8.3% | 0.8% |
每股收益（稀释后）IOSPRPRX
| Q4 25 | $1.90 | $0.49 | ||
| Q3 25 | $0.52 | $0.67 | ||
| Q2 25 | $0.94 | $0.07 | ||
| Q1 25 | $1.31 | $0.55 | ||
| Q4 24 | $-2.80 | $0.46 | ||
| Q3 24 | $1.33 | $1.21 | ||
| Q2 24 | $1.24 | $0.23 | ||
| Q1 24 | $1.65 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $292.5M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.3B | $9.7B |
| 总资产 | $1.8B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资IOSPRPRX
| Q4 25 | $292.5M | $618.7M | ||
| Q3 25 | $270.8M | $938.9M | ||
| Q2 25 | $266.6M | $631.9M | ||
| Q1 25 | $299.8M | $1.1B | ||
| Q4 24 | $289.2M | $929.0M | ||
| Q3 24 | $303.8M | $950.1M | ||
| Q2 24 | $240.2M | $1.8B | ||
| Q1 24 | $270.1M | $843.0M |
总债务IOSPRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益IOSPRPRX
| Q4 25 | $1.3B | $9.7B | ||
| Q3 25 | $1.3B | $9.6B | ||
| Q2 25 | $1.3B | $9.5B | ||
| Q1 25 | $1.3B | $9.8B | ||
| Q4 24 | $1.2B | $10.3B | ||
| Q3 24 | $1.2B | $10.3B | ||
| Q2 24 | $1.2B | $9.8B | ||
| Q1 24 | $1.2B | $9.9B |
总资产IOSPRPRX
| Q4 25 | $1.8B | $19.6B | ||
| Q3 25 | $1.8B | $19.3B | ||
| Q2 25 | $1.8B | $18.3B | ||
| Q1 25 | $1.8B | $17.6B | ||
| Q4 24 | $1.7B | $18.2B | ||
| Q3 24 | $1.8B | $18.0B | ||
| Q2 24 | $1.7B | $17.7B | ||
| Q1 24 | $1.7B | $16.1B |
负债/权益比IOSPRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $61.4M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $46.8M | — |
| 自由现金流率自由现金流/营收 | 10.3% | — |
| 资本支出强度资本支出/营收 | 3.2% | — |
| 现金转化率经营现金流/净利润 | 1.30× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $88.0M | — |
8季度趋势，按日历期对齐
经营现金流IOSPRPRX
| Q4 25 | $61.4M | $827.1M | ||
| Q3 25 | $39.3M | $702.6M | ||
| Q2 25 | $9.3M | $364.0M | ||
| Q1 25 | $28.3M | $596.1M | ||
| Q4 24 | $25.7M | $742.5M | ||
| Q3 24 | $73.5M | $703.6M | ||
| Q2 24 | $4.7M | $658.2M | ||
| Q1 24 | $80.6M | $664.6M |
自由现金流IOSPRPRX
| Q4 25 | $46.8M | — | ||
| Q3 25 | $25.0M | — | ||
| Q2 25 | $-3.7M | — | ||
| Q1 25 | $19.9M | — | ||
| Q4 24 | $13.6M | — | ||
| Q3 24 | $65.8M | — | ||
| Q2 24 | $-6.2M | — | ||
| Q1 24 | $69.9M | — |
自由现金流率IOSPRPRX
| Q4 25 | 10.3% | — | ||
| Q3 25 | 5.7% | — | ||
| Q2 25 | -0.8% | — | ||
| Q1 25 | 4.5% | — | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 14.8% | — | ||
| Q2 24 | -1.4% | — | ||
| Q1 24 | 14.0% | — |
资本支出强度IOSPRPRX
| Q4 25 | 3.2% | — | ||
| Q3 25 | 3.2% | — | ||
| Q2 25 | 3.0% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 2.5% | — | ||
| Q1 24 | 2.1% | — |
现金转化率IOSPRPRX
| Q4 25 | 1.30× | 3.86× | ||
| Q3 25 | 3.05× | 2.44× | ||
| Q2 25 | 0.40× | 12.06× | ||
| Q1 25 | 0.86× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 2.20× | 1.29× | ||
| Q2 24 | 0.15× | 6.45× | ||
| Q1 24 | 1.95× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IOSP
| Refinery And Performance | $147.0M | 32% |
| Personal Care | $99.7M | 22% |
| Oilfield Services | $93.1M | 20% |
| Other Fuel Specialties | $47.1M | 10% |
| Other Performance Chemicals | $40.0M | 9% |
| Home Care | $28.7M | 6% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
